Franklin Resources’s Relmada Therapeutics RLMD Stock Holding History

Franklin Resources’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-42,797	Closed	-$11.6K	–	3119
2025 Q1	$11.6K	Sell	42,797 -1,259,354	-97%	-$417K	﹤0.01%	2925
2024 Q4	$677K	Hold	1,302,151	–	–	﹤0.01%	2157
2024 Q3	$4.36M	Buy	1,302,151 +289,490	+29%	+$938K	﹤0.01%	1406
2024 Q2	$3.04M	Buy	1,012,661 +382,410	+61%	+$1.38M	﹤0.01%	1541
2024 Q1	$2.93M	Buy	+630,251	New	+$3.04M	﹤0.01%	1576
2021 Q4	–	Sell	-243,007	Closed	-$6.37M	–	2538
2021 Q3	$6.37M	Hold	243,007	–	–	﹤0.01%	1153
2021 Q2	$7.78M	Buy	243,007 +18,000	+8%	+$625K	﹤0.01%	1053
2021 Q1	$7.92M	Hold	225,007	–	–	﹤0.01%	1025
2020 Q4	$7.22M	Buy	225,007 +7	+0%	+$241	﹤0.01%	1022
2020 Q3	$8.46M	Hold	225,000	–	–	﹤0.01%	946
2020 Q2	$9.38M	Hold	225,000	–	–	﹤0.01%	880
2020 Q1	$7.67M	Hold	225,000	–	–	0.01%	845
2019 Q4	$8.78M	Buy	+225,000	New	+$6.84M	﹤0.01%	913

Other funds holding RLMD

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Corient Private Wealth Miami, Florida $72.2B AUM 27.85% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return

Franklin Resources's RLMD Position: Q2 2025 in Review

Franklin Resources sold out of Relmada Therapeutics (RLMD) in Q2 2025, closing a stake of 42,797 shares — an estimated $11.6K sold.

Franklin Resources first reported a position in RLMD in Q4 2019 and held it in 13 quarters. The position peaked at $9.38M in Q2 2020. 50 funds tracked by Wall St. Rank hold RLMD as of Q2 2025.

Franklin Resources reported no remaining Relmada Therapeutics position as of Q2 2025 after selling out during the quarter.
Franklin Resources sold 42,797 Relmada Therapeutics shares in Q2 2025, an estimated $11.6K.
Franklin Resources first reported a position in Relmada Therapeutics in Q4 2019 and held it in 13 quarters.
Franklin Resources's Relmada Therapeutics position peaked at $9.38M in Q2 2020.
50 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2025.

Based on Franklin Resources's 13F filing for Q2 2025, filed 12 Aug 2025.